Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.65 USD
Change Today -0.01 / -0.60%
Volume 48.2K
SNGX On Other Exchanges
Symbol
Exchange
Berlin
OTC BB
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

soligenix inc (SNGX) Snapshot

Open
$1.72
Previous Close
$1.66
Day High
$1.74
Day Low
$1.65
52 Week High
03/6/15 - $2.30
52 Week Low
12/19/14 - $0.91
Market Cap
41.5M
Average Volume 10 Days
86.7K
EPS TTM
$-0.39
Shares Outstanding
25.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SOLIGENIX INC (SNGX)

Related News

No related news articles were found.

soligenix inc (SNGX) Related Businessweek News

No Related Businessweek News Found

soligenix inc (SNGX) Details

Soligenix, Inc., a clinical stage biopharmaceutical company, is engaged in developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and various biodefense vaccines and therapeutics. The company operates in, BioTherapeutics and Vaccine/Biodefense. The BioTherapeutics segment develops proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including pediatric Crohn’s disease, acute radiation enteritis, and chronic graft-versus-host disease, as well as novel innate defense regulator technology for the treatment of oral mucositis. The Vaccines/BioDefense segment offers RiVax, a ricin toxin vaccine; VeloThrax, an anthrax vaccine; OrbeShield, a gastrointestinal acute radiation syndrome program; and SGX943, a melioidosis therapeutic. These vaccine programs are supported by the company’s heat stabilization technology, known as ThermoVax. The company has collaboration with Intrexon Corporation to focus on the joint development of a treatment for Melioidosis, a high priority biothreat and an area of unmet medical need. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was founded in 1987 and is headquartered in Princeton, New Jersey.

soligenix inc (SNGX) Top Compensated Officers

Chairman, Chief Execdutive Officer and Presid...
Total Annual Compensation: $641.0K
Acting Chief Financial Officer, Vice Presiden...
Total Annual Compensation: $276.0K
Compensation as of Fiscal Year 2013.

soligenix inc (SNGX) Key Developments

Soligenix, Inc. Announces Earnings Results for the Year Ended December 31, 2014

Soligenix, Inc. announced earnings results for the year ended December 31, 2014. The company's revenues for the year ended December 31, 2014 were $7.0 million as compared to $3.2 million for the prior year. The company's basic net loss was $6.7 million, or $0.32 per share, as compared to $10.1 million, or $0.65 per share, for the year ended December 31, 2014 and 2013 respectively.

Soligenix Announces Positive Recommendation by Data Review Committee on its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients

Soligenix, Inc. announced it has received a positive recommendation from the Data Review Committee (DRC) to continue enrolling into the company's Phase 2 study evaluating SGX942, as a treatment for oral mucositis in patients undergoing chemoradiation (CRT) therapy for head and neck cancer. Following DRC review of available data on the subjects enrolled in the trial, the committee recommended that enrollment include an additional 20 subjects randomized into either a single SGX942 dose group or the placebo group to allow for a more targeted assessment of the drug's potential effect and to inform final dose selection in this patient population. This Phase 2 study is a randomized, double-blind, dose-ranging, placebo-controlled trial, initially set to enroll approximately 75 subjects across 3 SGX942 dose groups and placebo, focused on demonstrating the safety and biologic activity of SGX942 in patients with tumors of the mouth and oropharynx who often experience debilitating oral mucositis as a consequence of tumor treatment with CRT. The primary efficacy assessment is the comparison of the incidence and/or duration of both ulcerative and severe oral mucositis throughout the subjects' 7 week course of CRT and for an additional 4 weeks thereafter. The study blind will remain in effect until completion of the trial.

Soligenix, Inc. Presents Data from its Recent Preclinical Study of Ricin Toxin Vaccine

Soligenix, Inc. announced that it presented data from its recent preclinical study that demonstrated the efficacy and safety of its heat-stabilized ricin toxin vaccine (RiVax) in a non-human primate (NHP) lethal aerosolized ricin exposure model. The data was presented in a poster session at the American Society of Microbiology (ASM) Biodefense and Emerging Diseases Research meeting on February 11, 2015 at Washington Marriott Wardman Park, 2660 Woodley Rd. NW in Washington, DC. Soligenix has been developing RiVax, its proprietary ricin toxin vaccine, in conjunction with its heat stabilization technology, ThermoVax, as a heat-stable biodefense vaccine. Vaccination with RiVax protected all animals from acute lethal death due to aerosolized ricin exposure, in contrast to unvaccinated animals that died within 40 hours. In the study, 12 animals were vaccinated with RiVax and 6 animals were given an injection of placebo (unvaccinated control). Each animal received 3 intramuscular injections, administered at time 0, 30 days and 60 days. Vaccination with RiVax was well tolerated with no evidence of elevated heart rate, respiration or temperature. All RiVax-vaccinated animals generated neutralizing antibodies after the third injection. To fully test the efficacy of the vaccine, all animals were exposed to an aerosol of ricin toxin 3-5 times the amount that is known to result in death of untreated animals. All RiVax-vaccinated animals survived exposure, while all unvaccinated control animals died within 40 hours, demonstrating a statistically significant (p<0.0001) improvement in survival. Moreover, the lungs of the RiVax™-vaccinated animals did not demonstrate any signs of irreversible damage, unlike those of the unvaccinated control animals.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNGX:US $1.65 USD -0.01

SNGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SNGX.
View Industry Companies
 

Industry Analysis

SNGX

Industry Average

Valuation SNGX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.2x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SOLIGENIX INC, please visit www.soligenix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.